Evidence map›Paper›PMID 30588556›Full record

ArticleClinical rheumatology2019

Functional implications of single nucleotide polymorphisms rs662 and rs854860 on the antioxidative activity of paraoxonase1 (PON1) in patients with rheumatoid arthritis.

Arkaitz Mucientes, Benjamín Fernández-Gutiérrez, Eva Herranz, Luis Rodriguez-Rodriguez, Jezabel Varadé, Elena Urcelay, José Ramón Lamas

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Article
  6. Association betweenAvicenna journal of medical biotechnology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Arkaitz MucientesInstituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC). UGC de Reumatología, Hospital Clínico San Carlos, Madrid, Spain.
Benjamín Fernández-GutiérrezInstituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC). UGC de Reumatología, Hospital Clínico San Carlos, Madrid, Spain. benjamin.fernandez@salud.madrid.org.ORCID http://orcid.org/0000-0002-6126-8786
Eva HerranzInstituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC). UGC de Reumatología, Hospital Clínico San Carlos, Madrid, Spain.
Luis Rodriguez-RodriguezInstituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC). UGC de Reumatología, Hospital Clínico San Carlos, Madrid, Spain.
Jezabel VaradéInstituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC). UGC de Inmunología, Hospital Clínico San Carlos, Madrid, Spain.
Elena UrcelayInstituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC). UGC de Inmunología, Hospital Clínico San Carlos, Madrid, Spain.
José Ramón LamasInstituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC). UGC de Reumatología, Hospital Clínico San Carlos, Madrid, Spain.
Hospital Clínico San Carlos · ESInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ES

Funding

Instituto de Salud Carlos III PI13/01863Instituto de Salud Carlos III RD16/0012/0004
6 · The paper itself

Abstract

backgroundAtherosclerosis leading to cardiovascular disease (CVD) is the main cause of mortality and morbidity in patients with rheumatoid arthritis (RA). Paraoxonase1 (PON1) is the best understood member of plasma paraoxonases with anti-atherogenic properties. PATIENTS AND

methodsSpanish RA (n = 549) consecutively recruited from 1 single center and 477 ethnically matched healthy controls were included in a case-control study. The concentration of PON1 was evaluated by means of an enzyme-linked immunosorbent sssay (ELISA). An arylesterase/paraoxonase assay kit was used to evaluate PON1 activity. Sample genotyping was performed by using TaqMan assays-on-demand. All results were expressed as medians ± interquartile range. One-way ANOVA comparisons were done using a nonparametric Kruskall-Wallis test. P values under 0.05 were considered to be significant.

resultsThe concentration of PON1 in the RA group was higher than in control group (p = 0.0003), although the differences were not significant when PON1 activities were compared between both groups. No significant differences were found related to distributions of rs662 genotypes in RA patients compared to healthy controls. Among rs854860 polymorphisms, overall genotype was widely distributed between RA patients and controls. Overall PON1 concentration in plasma was not significantly different between individuals carrying any of rs662 (p = 0.8501) or rs854860 (p = 0.2741) polymorphisms. Although PON1 levels were not associated with any of the SNPs in the study, differences appear when enzyme activities are compared for each SNP separately. CVD in RA patients correlate with increased PON1 levels and lower PON1 activity.

conclusionsAlthough protective role of PON1 against oxidative damage in vivo could be related to other activities, in our study arylesterase activity was useful to identify phenotypic differences with emphasis placed on two SNPs coding for nonconservative amino acid changes in the functional protein.

Indexed as

Polymorphism, Single NucleotideAdultAgedAntioxidantsArthritis, RheumatoidAryldialkylphosphataseCardiovascular DiseasesCase-Control StudiesFemaleGenotypeHumansMaleMiddle AgedSpainAntioxidantsAryldialkylphosphatasePON1 protein, humanCardiovascular diseaseGeneticsParaoxonase1Rheumatoid arthritis

Identifiers

PMID30588556
OpenAlexW2905735409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.